TXG logo

10x Genomics, Inc. Stock Price

NasdaqGS:TXG Community·US$2.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 27 Fair Values set on narratives written by author

TXG Share Price Performance

US$18.12
6.05 (50.12%)
US$18.08
Fair Value
US$18.12
6.05 (50.12%)
0.2% overvalued intrinsic discount
US$18.08
Fair Value
Price US$18.12
AnalystConsensusTarget US$18.08
AnalystLowTarget US$14.00
AnalystHighTarget US$18.00

TXG Community Narratives

AnalystConsensusTarget·
Fair Value US$18.08 0.2% overvalued intrinsic discount

Advanced Genomics Tools Will Shape Future Precision Medicine

0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
AnalystLowTarget·
Fair Value US$14 29.4% overvalued intrinsic discount

US Funding Cuts And Global Pressures Will Hamper Progress

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value US$18 0.7% overvalued intrinsic discount

Advanced Genomics Trends Will Unlock Precision Medicine

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$18.08
0.2% overvalued intrinsic discount
Revenue
2.95% p.a.
Profit Margin
16.15%
Future PE
28.06x
Price in 2029
US$23.1
US$14
29.4% overvalued intrinsic discount
Revenue
1.15% p.a.
Profit Margin
15.66%
Future PE
23.63x
Price in 2029
US$17.89
US$18
0.7% overvalued intrinsic discount
Revenue
7.88% p.a.
Profit Margin
14.22%
Future PE
26.05x
Price in 2028
US$22.36

Trending Discussion

Updated Narratives

TXG logo

TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside

Fair Value: US$18.08 0.2% overvalued intrinsic discount
20 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TXG logo

TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment

Fair Value: US$14 29.4% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TXG logo

Advanced Genomics Trends Will Unlock Precision Medicine

Fair Value: US$18 0.7% overvalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

2 Risks
2 Rewards

10x Genomics, Inc. Key Details

US$642.8m

Revenue

US$198.4m

Cost of Revenue

US$444.4m

Gross Profit

US$487.9m

Other Expenses

-US$43.5m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.34
69.13%
-6.77%
0%
View Full Analysis

About TXG

Founded
2012
Employees
1178
CEO
Serge Saxonov
WebsiteView website
www.10xgenomics.com

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Recent TXG News & Updates

Recent updates

No updates